Product Description
Syndromic Multiplex Diagnostics Markets: Strategies and Trends, Forecasts by Syndrome, Place, Product and Country with Market Analysis, Executive Guides and Customization 2022 to 2026
"COVID pandemic drives syndromic diagnostics into hypergrowth! Market explodes overnight..."
How will COVID-19 affect syndromic and infectious disease diagnostics? The COVID pandemic is ushering in a new world of infectious disease diagnostics and will continue to change more in the future. Can what was already a rapidly growing market expand even faster?
Are targeted tests for specific pathogens going to be obsolete? Will infectious disease testing move into the physician’s office or even the home?
Syndromic testing is proving itself in the market. players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against antimicrobial resistance (AMR). The two key trends of point of care (POC) testing and molecular diagnostics (MDx) are meeting with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. Learn about this market including the issues and outlooks.
In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.
The report forecasts the market size out to 2026 and includes detailed breakouts for 14 countries and 5 regions.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
Subscription deliverables:
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
Our facts and support = Your success.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
Assistance and additional breakout data relevant to your own area(s) of interest is available free of charge with the report (corporate license).
All report data is available in Excel format on request.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
